XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 482,452 shares, an increase of 31.7% from the November 30th total of 366,222 shares. Currently, 4.2% of the shares of the company are sold short. Based on an average daily volume of 93,126 shares, the days-to-cover ratio is presently 5.2 days. Based on an average daily volume of 93,126 shares, the days-to-cover ratio is presently 5.2 days. Currently, 4.2% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of research firms have recently commented on XOMA. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday. HC Wainwright dropped their price target on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Zacks Research downgraded XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 18th. Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, UBS Group set a $76.00 target price on XOMA Royalty in a report on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, XOMA Royalty currently has a consensus rating of “Hold” and an average target price of $60.60.

Insiders Place Their Bets

In other XOMA Royalty news, CEO Owen Hughes purchased 100,000 shares of the stock in a transaction on Thursday, December 4th. The shares were purchased at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the acquisition, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. This represents a 5,000.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 9.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its holdings in shares of XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in XOMA Royalty in the 2nd quarter valued at about $116,000. Finally, BNP Paribas Financial Markets raised its stake in shares of XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 2,346 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Price Performance

NASDAQ:XOMA opened at $26.59 on Thursday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm has a market cap of $329.18 million, a PE ratio of 35.93 and a beta of 0.94. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The company’s 50-day moving average price is $30.55 and its two-hundred day moving average price is $31.09.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The firm had revenue of $9.35 million for the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. On average, equities analysts anticipate that XOMA Royalty will post -1.41 EPS for the current fiscal year.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.